Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc
NDA FilingCRLDasynocNegative
AI Analysis
Summary
Xspray Pharma received a Complete Response Letter from the FDA for Dasynoc due to outstanding GMP observations and additional commercial information requests, representing a regulatory setback for the application.
Outcome Details
Complete Response Letter received relating to outstanding GMP observations at NerPharMa and request for additional commercial information
Importance:8/10
Sentiment:
-0.90
FDACRLGMPmanufacturingregulatory setback
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on August 19, 2026 10:08 PM